Consolidated quarterly revenue of KRW 156.8 billion, annual revenue of KRW 267.5 billion… Continued investment results in ongoing losses<o:p></o:p>

Revenue growth driven by IDT Biologika’s Q4 performance, aiming for IDT turnaround this year<o:p></o:p>

Strengthened partnership with Sanofi and expanded domestic and international sales of key products expected to improve financial performance<o:p></o:p>

provement are further heightened by strengthened strategic collaboration with Sanofi.